Company Number: 14448784

Analysis Date: 2025-07-19 12:24 UTC

Financial Health Assessment Report for Cardiovision Ltd

---

1. Financial Health Score: B

Explanation:
Cardiovision Ltd exhibits a sound financial position for a newly incorporated specialist medical practice. The company shows a healthy balance sheet with positive net current assets and shareholders’ funds, indicating good initial capitalization and liquidity. However, the absence of income statement details and limited operational history restrain a top-tier rating, pending evidence of sustainable profitability and cash flow generation.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Current Assets	49,261	Strong short-term resources, mainly cash, indicating good liquidity ("healthy cash flow reserve").
Cash at Bank	49,061	High cash balance relative to liabilities, a positive sign of readily available funds.
Debtors	200	Minimal receivables, suggesting limited credit exposure or early stage customer base.
Current Liabilities	14,565	Manageable short-term obligations, comfortably covered by current assets.
Net Current Assets (Working Capital)	34,696	Positive working capital ("financial stamina") enabling smooth operations without liquidity distress.
Fixed Assets (Net)	12,839	Investment in tangible assets, likely medical equipment, supporting operational capacity.
Shareholders’ Funds (Equity)	47,535	Solid equity base providing financial stability and buffer against losses.
Called-up Share Capital	200	Nominal share capital; majority of equity is retained earnings, indicating early profitability or capital injection.

---

3. Diagnosis

Cardiovision Ltd is in the early stages of its financial life cycle, with a sturdy “financial heartbeat” demonstrated by positive net assets and liquidity. The company’s substantial cash reserves relative to liabilities resemble a patient with a strong pulse and no signs of immediate distress. The low level of debt mitigates financial risk, and the tangible fixed assets suggest investment in essential medical infrastructure.

However, the absence of published turnover and profit figures (income statement not filed due to abridged accounts filing option) limits insight into operational profitability and cash flow from core activities. This “symptom” indicates the company may still be in the investment and setup phase, or it is choosing minimal disclosure typical for small entities.

The company’s status as a private limited entity in a specialist medical practice niche suggests a focus on specialised services with potential for steady revenue streams as the business matures. The directors and persons of significant control are experienced professionals in the medical field, which bodes well for strategic governance.

---

4. Recommendations

• Enhance Financial Transparency:
  Consider moving beyond abridged accounts in future filings to provide stakeholders with clearer visibility into profitability, operating cash flows, and growth trends. This helps diagnose operational "vital signs" more accurately.

• Monitor Liquidity and Cash Flow:
  Maintain strong cash reserves to support working capital needs and unexpected expenses, ensuring continued “healthy circulation” of funds.

• Profitability Tracking:
  Develop robust internal financial reporting to monitor income, costs, and margins closely. Early detection of “financial symptoms” such as margin compression or rising expenses will allow prompt corrective action.

• Asset Utilisation:
  Regularly assess fixed asset efficiency to confirm that investments in medical equipment and facilities contribute positively to revenue generation and patient service capacity.

• Growth and Funding Strategy:
  Plan carefully for scaling operations, balancing equity funding with prudent debt to avoid “financial stress” that could impair liquidity or solvency.

• Governance and Compliance:
  Maintain timely filing of all statutory accounts and confirmation statements to prevent penalties and preserve corporate reputation.

---